We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Molecular subtypes in male breast cancer.
- Authors
Dumitru, Mihaela; Rebegea, Laura; Crăescu, Mihaela; Firescu, Dorel; Șerban, Cristina
- Abstract
Male breast cancer (MBC) is a heterogeneous disease, being <1% from breast cancer, with differences respect median age at diagnosis, frequency of estrogen positive patients. Methods and material. This study involves 34 breast cancer male patients, diagnosed and treated in Oncology and Radiotherapy Department of „Sf. Ap. Andrei” Emergency Clinical Hospital, Galati for which there were available immunohistochemical tests (IHC) of 52 male breast cancer treated in our hospital in period: 1st January 1993 - 31st December 2016. Molecular subtype’s distributions and performed multimodal treatment were analyzed. Results. Median age of analyzed patients was 63 years old (range 45-79 years), with a greater frequency of 60-69 years old patients; a percent of 38.24% of cases presented IIIB stage of disease. Predominant histology was invasive ductal carcinoma in 88.24% of cases. Respect IHC, Luminal A molecular subtype was found in 64.71% of cases, Luminal B Her2-neu negative in 29.41%, luminal B, Her2-neu positive in 2.94%, and basal like in 2.94% of cases. Multimodal treatment involved surgery, external beam radiotherapy, chemotherapy and hormonal therapy (HT). HT with Tamoxifen performed 88.24% of cases. One patient developed, two years from breast cancer diagnosis, a second malignancy - prostate cancer. Histological characteristics respect molecular subtypes were analyzed but the statistical tests did not identify significant differences of parametric variance. Due to the high number of patients lost form follow up, we did not perform survival studies. Conclusions . Because the rarity of cases, MBC represents a specific subgroup in which the management principles are applied starting from therapeutically guides of female breast cancer. We notice a predominance of invasive ductal carcinoma histology, of Luminal A molecular subtype, with a higher frequency of Ki67<20% values, and grading G2. Over expression of Her2-neu is known as prognostic factor associated with low survival, in MBC. Low incidence of basal-like molecular subtype in MBC can be associated with high median age at diagnosis in men (66 years old) respect women and with low frequency of BRCA1 mutation in men.
- Subjects
BREAST cancer; COMBINED modality therapy; DUCTAL carcinoma
- Publication
Oncolog-Hematolog, 2017, Issue 39, p56
- ISSN
2066-8716
- Publication type
Abstract